(PDF) OA03 Afatinib Followed by Osimertinib in Real-World

OA03 Afatinib Followed by Osimertinib in Real-World Patients With EGFR Mutation-Positive Advanced NSCLC: The Giotag Study

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.10.013

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

December 1, 2018

Authors

Publisher

Elsevier BV

Related search

P1.01-28 Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients With EGFR Mutation-Positive Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

MA02.03 ASTRIS: A Real World Treatment Study of Osimertinib in Patients With EGFR T790m-Positive NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

Real-World Experience of Afatinib as a First-Line Therapy for Advanced EGFR Mutation-Positive Lung Adenocarcinoma

English

MA26.10 CNS Activity of Ramucirumab in Combination With Osimertinib in Patients With Advanced T790m-Positive EGFR-Mutant NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC

Lung Cancer Management

English

MA15.10 Loss of T790M Mutation Is Associated With Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.13-11 PRO-CTCAE Toxicities in Advanced NSCLC Patients With EGFR Mutations: A Real World Assessment

Journal of Thoracic Oncology

Respiratory Medicine

English

MA15.11 Real World Biomarker Testing and Treatment Patterns in Patients With Advanced NSCLC Receiving EGFR-TKIs

Journal of Thoracic Oncology

Respiratory Medicine

English

Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC

Cancer Research

English